Topic:

Patents

Latest Headlines

Latest Headlines

Supreme Court pitches patent fight over Shire's Lialda after Teva ruling

The ripple effects from last week's Teva v. Sandoz ruling have begun. The U.S. Supreme Court sent three patent fights back to a lower court in light of that ruling, which ordered the Federal Circuit Court to defer to district-level findings on patent claims unless a "clear error" had been made.

Trans-Pacific Partnership push waits on cue from Obama's India visit

SINGAPORE-- India is not a member of the 12-nation Trans-Pacific Partnership, but its intellectual property rules governing pharmaceutical patents lie at the core of a dispute ginning up this year to reach a final agreement. India's resistance to relaxing its rules has been a model for the emerging-market members of the TPP to seek similar compulsory licensing arrangements for generic drugs.

U.S. Supreme Court ruling on Copaxone triggers questions in generics-minded India

The U.S. Supreme Court may have handed the Delhi High Court in India something else to ponder in mulling the use of compulsory licensing ahead of a possible hearing next month.

Don't use generic Lyrica for pain, Pfizer warns U.K. providers--or else

Pfizer has written doctors in the U.K. warning them not to prescribe Lyrica knockoffs to treat neuropathic pain. Seems the company still has a live patent covering Lyrica's use against that type of nerve pain.

Gilead's Sovaldi the latest casualty in India's patent crusade

India's intellectual-property police nixed a key patent on Gilead Sciences' hepatitis C drug Sovaldi, opening the door for cheap generic copies from domestic drugmakers such as Natco Pharma. It's the latest blow to a multinational drugmaker's ambitions in India, which remains one of the fastest-growing drug markets in the world.

Hedge fund exec aims new legal weapon at Big Pharma's 'evergreened' patents

As companies, regulators and advocacy groups lobby to bring certain branded products off-patent, a new voice is joining the chorus. U.S. hedge fund manager Kyle Bass, best known for predicting the subprime mortgage crisis in 2008, said he plans to challenge questionable drug patents from industry heavyweights.

Otsuka spends $3.5B for Avanir--and patent-cliff protection

Otsuka's patent cliff is coming, with the expiration date on best-seller Abilify's IP shield just around the corner. But now, the Japanese pharma has signed a $3.5 billion agreement to pick up Avanir Pharmaceuticals that could help soften the blow.

If Teva wanted a clear sign from Supreme Court on Copaxone, no such luck

Teva's been waiting a long time to get its Copaxone patent appeal before the Supreme Court. And now that the court has heard oral arguments, it seems to be divided on the issue.

MSF urges Indian PM to stand firm against Big Pharma's patent lobbying

As Indian Prime Minister Narendra Modi travels to the U.S. to meet with officials, Doctors Without Borders (MSF) has one message for him: Don't back down on drug patents.

Bristol-Myers socks Merck's brand-new Keytruda with PD-1 patent suit

Bristol-Myers Squibb is doing its best to rain on Merck & Co.'s immunotherapy parade. No sooner had Merck won FDA approval for its brand-new cancer drug Keytruda (pembrolizumab) than Bristol-Myers and its partner Ono Pharmaceutical slapped it with a patent-infringement lawsuit.